PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12012107-6	2002	In addition, neutralizing anti-IFN-gamma monoclonal antibody (mAb), or neutralizing anti-tumor necrosis factor (TNF) mAb reduced the relapse-free survival of mice treated with CY followed by DNP-modified ATC vaccine, indicating the importance of both cytokines for the realization of the anti-metastatic effect of this therapeutic protocol.	dnp	191-194	tumor necrosis factor	Mus musculus	84-110	
12012107-6	2002	In addition, neutralizing anti-IFN-gamma monoclonal antibody (mAb), or neutralizing anti-tumor necrosis factor (TNF) mAb reduced the relapse-free survival of mice treated with CY followed by DNP-modified ATC vaccine, indicating the importance of both cytokines for the realization of the anti-metastatic effect of this therapeutic protocol.	dnp	191-194	tumor necrosis factor	Mus musculus	112-115	
12963148-5	2003	When XF (0.1mg/ml) was added, the secretion of tumor necrosis factor-alpha (TNF-alpha) from anti-dinitrophenyl (DNP) IgE antibody-stimulated mast cells was inhibited by 56%.	dnp	112-115	tumor necrosis factor	Mus musculus	47-74	
12963148-5	2003	When XF (0.1mg/ml) was added, the secretion of tumor necrosis factor-alpha (TNF-alpha) from anti-dinitrophenyl (DNP) IgE antibody-stimulated mast cells was inhibited by 56%.	dnp	112-115	tumor necrosis factor	Mus musculus	76-85